https://ascendispharmamedical.us/disease-state-education/adult-growth-hormone-deficiency-overview/ 2025-12-17T16:05:23+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_GH_Adult-GHD-Disease-State-Overview_Infographic_Medical-Website.jpeg https://ascendispharmamedical.us/disease-state-education/achondroplasia-overview/ 2025-12-17T17:10:53+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_CNP_Achondroplasia-Disease-State-Overview_Infographic_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/efficacy-and-safety-of-palopegteriparatide-treatment-in-adults-with-hypoparathyroidism-3-year-results-from-the-phase-3-pathway-trial/ 2025-12-22T18:38:13+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_PTH_Khan_ENDO-2025_3-Year-Results-PaTHway-Trial_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/transcon-pth-enables-independence-from-conventional-therapy-while-maintaining-normal-serum-calcium-in-adults-with-chronic-postsurgical-hypoparathyroidism-results-from-a-sub-analysis-of-the-pathway-ph/ 2025-12-22T18:40:38+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_PTH_Schneider_ATA-2023_PaTHway-Sub-Analysis_Poster_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/long-term-efficacy-and-safety-of-palopegteriparatide-treatment-in-adults-with-chronic-hypoparathyroidism-4-year-results-from-the-phase-2-path-forward-trial/ 2025-12-22T18:41:24+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_PTH_Palermo_ECE-2025_PaTH-Forward-4-Year-Results_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/sustained-improvement-in-skeletal-dynamics-and-renal-function-with-palopegteriparatide-in-adults-with-chronic-hypoparathyroidism-2-year-results-from-the-phase-3-pathway-trial/ 2025-12-22T18:42:20+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_PTH_Kohlmeier_AACE-2025_2-Year-PaTHway-Skeletal-and-Renal-Results_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/header-here-33/ 2025-12-22T18:42:54+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_PTH_Rubin_ASBMR-2025_PaTH-Forward-4-Year-Skeletal-Dynamics_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/practical-management-of-pediatric-growth-hormone-deficiency-with-lonapegsomatropin-tcgd/ 2025-12-22T18:48:52+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_GH_Lipman_PENS-2023_Management-of-pGHD-with-Lonapegsomatropin_Poster_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/safety-and-effectiveness-of-lonapegsomatropin-in-the-skybright-registry-study-analysis-of-the-first-100-patients-enrolled-with-1-year-of-follow-up/ 2025-12-22T18:49:46+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_GH_Sather_PENS-2025_SkybriGHt-Registry-Study_Poster_Medical-Website.jpeg https://ascendispharmamedical.us/disease-state-education/pediatric-growth-hormone-deficiency-overview/ 2025-12-22T19:00:12+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_GH_Pediatric-GHD-Disease-State-Overview_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/improvements-in-lower-extremity-alignment-are-associated-with-physical-functioning-in-children-with-achondroplasia-treated-with-navepegritide-52-week-results-from-the-approach-trial/ 2025-12-22T22:29:53+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_CNP_Ward_ASBMR-2025_ApproaCH-52-Wk-Lower-Limb-Alignment-and-ACEM-PF_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/transcon-cnp-navepegritide-improved-physical-functioning-in-children-with-achondroplasia-in-the-approach-trial/ 2025-12-22T22:30:10+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_CNP_Abuzzahab_PES-2025_ApproaCH-52-Week-Physical-Functioning_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/once-weekly-lonapegsomatropin-transcon-hgh-added-to-once-weekly-navepegritide-transcon-cnp-in-children-with-achondroplasia-26-week-results-from-the-phase-2-coach-trial-asbmr-2025/ 2025-12-23T20:13:36+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_CNP_McDonnell_ASBMR-2025_COACH-26-Week-Results_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/results-of-the-foresighttrial-support-the-efficacy-and-safety-of-once-weekly-lonapegsomatropinin-adults-with-growth-hormone-deficiency/ 2026-01-08T14:55:07+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_GH_Biller_ENDO-2024_foresiGHt-Results_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/peer-reviewed-manuscripts/average-igf-1-prediction-for-once-weekly-lonapegsomatropinin-children-with-growth-hormone-deficiency/ 2026-01-08T14:55:46+00:00 https://ascendispharmamedical.us/congress-materials/the-majority-of-children-with-pediatric-growth-hormone-deficiency-treated-with-lonapegsomatropinfor-up-to-6-years-met-or-exceeded-average-parental-height-sds-final-results-of-enlighten/ 2026-01-08T14:59:18+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_GH_Vlachopapadopoulou_ESPE-2023_enliGHten-Final-Analysis_Poster_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/design-of-the-new-insightstrial-a-multicenter-phase-2-randomized-open-label-active-controlled-study-to-investigate-the-safety-tolerability-and-efficacy-of-lonapegsomatropin-tcgdin-prepubertal-i/ 2026-01-08T15:00:23+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_GH_Klein_ENDO-2023_Design-of-New-InsiGHts_Poster_Medical-Website.jpeg https://ascendispharmamedical.us/congress-materials/sustained-improvement-in-renal-function-vith-palopegteriparatide-in-adults-with-chronic-hypoparathyroidism-2-year-results-from-the-phase-3-pathway-trial/ 2026-01-08T15:01:14+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/US_PTH_Schwarz_ECE-2024_PaTHway-2-Year-Renal-Final-Analysis_Oral-Pres_Medical-Website.jpeg https://ascendispharmamedical.us/peer-reviewed-manuscripts/once-weekly-transconcnp-navepegritide-in-children-with-achondroplasia-accomplish-a-phase-2-multicentre-randomised-double-blind-placebo-controlled-dose-escalation-trial/ 2026-01-08T15:03:47+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/early-u-s-real-world-treatment-patterns-and-outcomes-in-palopegteriparatide-treatment-for-patients-with-hypoparathyroidism/ 2026-01-08T15:04:16+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/palopegteriparatide-treatment-improves-renal-function-in-adults-with-chronic-hypoparathyroidism-1-year-results-from-the-phase-3-pathwaytrial/ 2026-01-08T15:05:09+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/efficacy-and-safety-of-transcon-pth-in-adults-with-hypoparathyroidism-52-week-results-from-the-phase-3pathwaytrial/ 2026-01-08T15:05:33+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/efficacy-and-safety-of-parathyroid-hormone-replacement-with-transcon-pth-in-hypoparathyroidism-26-week-results-from-the-phase-3-pathway-trialkhan/ 2026-01-08T15:06:02+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/path-forward-a-randomized-double-blind-placebo-controlled-phase-2-trial-of-transcon-pth-in-adult-hypoparathyroidism/ 2026-01-08T15:06:15+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/design-and-preclinical-development-of-transconpth-an-investigational-sustained%e2%80%90release-pth-replacement-therapy-for-hypoparathyroidism/ 2026-01-08T15:13:20+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/a-randomized-double-blind-placebo-controlled-first-in-human-phase-1-trial-of-transconpth-in-healthy-adults/ 2026-01-08T15:13:23+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/weekly-lonapegsomatropinin-treatment-naive-children-with-growth-hormone-deficiency-the-phase-3-heighttrial/ 2026-01-08T16:15:07+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/a-randomized-phase-2-study-of-long-acting-transcongh-vs-daily-gh-in-childhood-gh-deficiency/ 2026-01-08T16:16:29+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/a-randomized-phase-2-study-of-long-acting-transcongh-vs-daily-gh-in-childhood-gh-deficiency-2/ 2026-01-08T16:18:06+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/phase-1-safety-tolerability-pharmacokinetics-and-pharmacodynamics-results-of-a-long-acting-c-type-natriuretic-peptide-prodrug-transcon-cnp/ 2026-01-08T16:26:11+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/safety-and-efficacy-of-lonapegsomatropinin-children-with-growth-hormone-deficiency-enlightentrial-2-yearresults/ 2026-01-08T22:39:32+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/switching-to-weekly-lonapegsomatropinfrom-daily-somatropin-in-children-with-growth-hormone-deficiency-the-flighttrial/ 2026-01-08T22:39:52+00:00 https://ascendispharmamedical.us/disease-state-education/hypoparathyroidism-overview/ 2026-01-09T17:33:31+00:00 https://ascendispharmamedical.us/wp-content/uploads/2025/12/THUMB_US_PTH_Hypoparathyroidism-Disease-State-Overview_Infographic_Medical-Website-1.png https://ascendispharmamedical.us/disease-state-education/prevalence-treatment-patterns-and-characteristics-of-us-adults-with-confirmed-or-at-risk-for-growth-hormone-deficiency/ 2026-02-10T15:55:06+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/efficacy-and-safety-of-once-weekly-lonapegsomatropin-in-adults-with-growth-hormone-deficiency-foresight-trial-results/ 2026-03-16T16:52:50+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/palopegteriparatide-for-adults-with-chronic-hypoparathyroidism-skeletal-dynamics-through-3-years-of-the-phase-2-path-forward-trial/ 2026-03-16T16:54:12+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/patient-reported-outcomes-in-palopegteriparatide-treated-adults-with-hypoparathyroidism-path-forward-trial-extension/ 2026-03-16T16:56:43+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/longitudinal-observation-of-children-with-achondroplasia-findings-from-a-global-natural-history-study-achieve/ 2026-03-16T16:57:16+00:00 https://ascendispharmamedical.us/congress-materials/us_pth_gosmanova_asn-2025_path-forward-and-pathway-pooled-renal-analysis_poster_medical-website-med-us-tc-pth-2600035-https-medicalaff1stg-wpenginepowered-com-congress-materials-scientific-library/ 2026-04-22T19:12:10+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/04/US_CNP_Savarirayan_ACMG-2026_Results-of-ApproaCH-Open-Label-Extension_Oral-Pres_Medical-Website_thumb.png https://ascendispharmamedical.us/congress-materials/us_pth_gosmanova_asn-2025_path-forward-and-pathway-pooled-renal-analysis_poster_medical-website-med-us-tc-pth-2600035/ 2026-04-22T21:22:27+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/04/US_PTH_Gosmanova_ASN-2025_PaTH-Forward-and-PaTHway-Pooled-Renal-Analysis_Poster_Medical-Website_thumb.png https://ascendispharmamedical.us/disease-state-education/idiopathic-short-stature-overview/ 2026-05-19T17:13:14+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/05/US_GH_Idiopathic-Short-Stature-Overview_Infographic_Medical-Website.png https://ascendispharmamedical.us/disease-state-education/small-for-gestational-age-without-catch-up-growth-overview/ 2026-05-19T17:13:45+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/05/US_GH_SGA-Without-Catch-Up-Growth-Overview_Infographic_Medical-Website.png https://ascendispharmamedical.us/disease-state-education/turner-syndrome-overview/ 2026-05-19T17:14:16+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/05/US_GH_Turner-Syndrome-Overview_Infographic_Medical-Website-copy.png https://ascendispharmamedical.us/disease-state-education/shox-deficiency-overview/ 2026-05-19T17:14:35+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/05/US_GH_SHOX-Deficiency-Overview_Infographic_Medical-Website.png https://ascendispharmamedical.us/disease-state-education/us_pth_hypoparathyroidism-and-renal-function_infographic_medical-website-med-us-tc-pth-2600039/ 2026-05-19T17:31:17+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/04/US_PTH_Hypoparathyroidism-and-Renal-Function_Infographic_Medical-Website-1-copy.png https://ascendispharmamedical.us/congress-materials/long-term-safety-and-efficacy-of-lonapegsomatropinin-adults-with-growth-hormone-deficiency-results-from-a-52-week-open-label-extension-trial/ 2026-05-19T18:17:48+00:00 https://ascendispharmamedical.us/wp-content/uploads/2026/05/US_GH_Silverstein_AACE-2026_foresiGHt-Extension-Week-52-Results_Oral-Pres_Medical-Website.png https://ascendispharmamedical.us/peer-reviewed-manuscripts/the-rationale-and-design-of-transcongrowth-hormone-for-the-treatment-of-growth-hormone-deficiency/ 2026-05-21T13:17:58+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/once-weekly-navepegritide-in-children-with-achondroplasia-the-approach-randomized-clinical-trial/ 2026-06-11T21:17:57+00:00 https://ascendispharmamedical.us/peer-reviewed-manuscripts/children-with-growth-hormone-deficiency-treated-with-lonapegsomatropindemonstrated-sustained-height-improvements-for-up-to-6-years-enlightentrial-final-results/ 2026-06-17T17:29:52+00:00